Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin
- PMID: 17560554
- PMCID: PMC1920586
- DOI: 10.1016/j.bcp.2007.04.024
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin
Abstract
HERG (human ether-à-go-go-related gene) encodes channels responsible for the cardiac rapid delayed rectifier potassium current, I(Kr). This study investigated the effects on HERG channels of doxepin, a tricyclic antidepressant linked to QT interval prolongation and cardiac arrhythmia. Whole-cell patch-clamp recordings were made at 37 degrees C of recombinant HERG channel current (I(HERG)), and of native I(Kr) 'tails' from rabbit ventricular myocytes. Doxepin inhibited I(HERG) with an IC(50) value of 6.5+/-1.4 microM and native I(Kr) with an IC(50) of 4.4+/-0.6 microM. The inhibitory effect on I(HERG) developed rapidly upon membrane depolarization, but with no significant dependence on voltage and with little alteration to the voltage-dependent kinetics of I(HERG). Neither the S631A nor N588K inactivation-attenuating mutations (of residues located in the channel pore and external S5-Pore linker, respectively) significantly reduced the potency of inhibition. The S6 point mutation Y652A increased the IC(50) for I(HERG) blockade by approximately 4.2-fold; the F656A mutant also attenuated doxepin's action at some concentrations. HERG channel blockade is likely to underpin reported cases of QT interval prolongation with doxepin. Notably, this study also establishes doxepin as an effective inhibitor of mutant (N588K) HERG channels responsible for variant 1 of the short QT syndrome.
Figures








Similar articles
-
Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.J Mol Cell Cardiol. 2006 Jan;40(1):107-18. doi: 10.1016/j.yjmcc.2005.09.017. Epub 2005 Nov 9. J Mol Cell Cardiol. 2006. PMID: 16288909
-
Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.Biochem Biophys Res Commun. 2001 Feb 9;280(5):1243-50. doi: 10.1006/bbrc.2001.4269. Biochem Biophys Res Commun. 2001. PMID: 11162661
-
Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. doi: 10.1007/s00210-004-0931-8. Epub 2004 Apr 20. Naunyn Schmiedebergs Arch Pharmacol. 2004. PMID: 15098086
-
The impact of I(Kr) blockade on medicinal chemistry programs.Curr Top Med Chem. 2008;8(13):1128-39. doi: 10.2174/156802608785700034. Curr Top Med Chem. 2008. PMID: 18782008 Review.
-
Preclinical cardiovascular risk assessment in modern drug development.Toxicol Sci. 2007 May;97(1):4-20. doi: 10.1093/toxsci/kfm026. Epub 2007 Mar 9. Toxicol Sci. 2007. PMID: 17351262 Review. No abstract available.
Cited by
-
Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin.Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):73-83. doi: 10.1007/s00210-008-0289-4. Epub 2008 May 6. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18458880
-
Sudden death in patients receiving drugs tending to prolong the QT interval.Br J Clin Pharmacol. 2009 Nov;68(5):743-51. doi: 10.1111/j.1365-2125.2009.03496.x. Br J Clin Pharmacol. 2009. PMID: 19916999 Free PMC article.
-
From linked open data to molecular interaction: studying selectivity trends for ligands of the human serotonin and dopamine transporter.Medchemcomm. 2016 Sep 14;7(9):1819-1831. doi: 10.1039/c6md00207b. Epub 2016 Jul 22. Medchemcomm. 2016. PMID: 27891211 Free PMC article.
-
Effects of amiodarone on short QT syndrome variant 3 in human ventricles: a simulation study.Biomed Eng Online. 2017 Jun 7;16(1):69. doi: 10.1186/s12938-017-0369-0. Biomed Eng Online. 2017. PMID: 28592292 Free PMC article.
-
Precision Medicine in Antidepressants Treatment.Handb Exp Pharmacol. 2023;280:131-186. doi: 10.1007/164_2023_654. Handb Exp Pharmacol. 2023. PMID: 37195310 Review.
References
-
- Viskin S. Long QT syndromes and torsade de pointes. Lancet. 1999;354:1625–1633. - PubMed
-
- Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications report on a policy conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219–233. - PubMed
-
- Shah R.R. Drugs QT interval prolongation and ICH E14—the need to get it right. Drug Safety. 2005;28:115–125. - PubMed
-
- Witchel H.J., Hancox J.C. Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol. 2000;27:753–766. - PubMed
-
- Vandenberg J.I., Walker B.D., Campbell T.J. HERG K+ channels: friend and foe. Trends Pharmacol Sci. 2001;22:240–246. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources